Structure Therapeutics, Inc. (GPCR)
49.53
+0.52
(+1.06%)
USD |
NASDAQ |
Aug 25, 14:37
Structure Therapeutics Enterprise Value : 2.154B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.154B |
| August 21, 2026 | 2.160B |
| August 20, 2026 | 2.261B |
| August 19, 2026 | 2.519B |
| August 18, 2026 | 2.476B |
| August 17, 2026 | 2.492B |
| August 14, 2026 | 2.546B |
| August 13, 2026 | 2.559B |
| August 12, 2026 | 2.503B |
| August 11, 2026 | 2.376B |
| August 10, 2026 | 2.495B |
| August 07, 2026 | 2.448B |
| August 06, 2026 | 2.411B |
| August 05, 2026 | 2.262B |
| August 04, 2026 | 2.199B |
| August 03, 2026 | 2.108B |
| July 31, 2026 | 2.085B |
| July 30, 2026 | 2.187B |
| July 29, 2026 | 2.036B |
| July 28, 2026 | 2.074B |
| July 27, 2026 | 2.131B |
| July 24, 2026 | 2.162B |
| July 23, 2026 | 2.281B |
| July 22, 2026 | 2.254B |
| July 21, 2026 | 2.178B |
| Date | Value |
|---|---|
| July 20, 2026 | 2.009B |
| July 17, 2026 | 2.116B |
| July 16, 2026 | 1.942B |
| July 15, 2026 | 2.197B |
| July 14, 2026 | 2.266B |
| July 13, 2026 | 2.341B |
| July 10, 2026 | 2.464B |
| July 09, 2026 | 2.591B |
| July 08, 2026 | 2.573B |
| July 07, 2026 | 2.697B |
| July 06, 2026 | 2.563B |
| July 02, 2026 | 2.470B |
| July 01, 2026 | 2.375B |
| June 30, 2026 | 2.486B |
| June 29, 2026 | 2.221B |
| June 26, 2026 | 2.080B |
| June 25, 2026 | 1.976B |
| June 24, 2026 | 1.970B |
| June 23, 2026 | 1.789B |
| June 22, 2026 | 1.782B |
| June 18, 2026 | 1.711B |
| June 17, 2026 | 1.745B |
| June 16, 2026 | 1.597B |
| June 15, 2026 | 1.608B |
| June 12, 2026 | 1.598B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.220T |
| Novo Nordisk A/S | 171.54B |
| Pfizer Inc. | 211.20B |
| Tarsus Pharmaceuticals, Inc. | 2.790B |
| Johnson & Johnson | 685.82B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -106.33M |
| Total Expenses (Quarterly) | 106.33M |
| EPS Diluted (Quarterly) | -1.464 |
| Earnings Yield | -6.22% |
| Normalized Earnings Yield | -6.465 |